Proteomics,Multiomics

Dataset Information

7

A Circulating Antibody Panel for Pre-transplant Prediction of FSGS Recurrence after Kidney Transplantation


ABSTRACT: Recurrence of focal segmental glomerulosclerosis (rFSGS) after kidney transplantation is a cause of early and accelerated graft loss. Immuneadsorption can alleviate renal dysfunction and suggests that circulating antibodies (Ab) are likely implicated in disease pathogenesis. To evaluate pathogenic Ab in rFSGS, we processed 141 unique serum samples from patients with and without primary rFSGS (n=64) and 34 non-FSGS control, transplanted at five (US and EU) hospitals. 9000 antigens were screened in pre-transplant sera by protein arrays and 10 Ab targeting glomerular antigens were selected for ELISA validation. A panel of 7 Ab (CD40, PTPRO, CGB-5, FAS, P2RY11, SNRPB2 and APOL2) could predict post-transplant FSGS recurrence with 92% accuracy. Pre-transplant elevation of anti-CD40 Ab levels alone had a substantial impact (78% accuracy) on the identification of rFSGS risk after transplantation. Epitope mapping of CD40 with customized peptide arrays and rFSGS sera demonstrated altered immunogenicity of the extracellular CD40 domain in rFSGS. Immunohistochemistry of CD40 demonstrated a differential expression of these antigens in FSGS compared to non-FSGS. Anti-CD40 Ab purified from rFSGS patients were uniquely pathogenic in human podocyte cultures; injection of these Ab resulted in heightened proteinuria, independently and in combination with suPAR in a rodent model, abrogated by injection of monoclonal Ab to CD40. In conclusion, a panel of 7 Ab can identify primary FSGS patients at high risk of recurrence prior to transplantation, allowing for customized therapies and improved patient selection for transplant. Intra-renal CD40 is an important axis of disease pathogenesis, and human trials of anti-CD40 therapies are warranted to evaluate their efficacy in preventing rFSGS and improving graft survival. The purpose of the study was to identify potential auto-Abs associated with rFSGS. We used a discovery set of pre-transplant sera from 20 unique patients with biopsy confirmed diagnosis of primary FSGS as their cause of ESRD, of which 10 had progressed to rFSGS within the first post-transplant year and 10 did not have recurrence of proteinuria or histological disease after transplantation (nrFSGS).

OTHER RELATED OMICS DATASETS IN: PRJNA245423

ORGANISM(S): Homo sapiens  

SUBMITTER: Maarten Naesens   Changli Wei  Marianne Delville  Szu-Chuan Hsieh  Minnie Sarwal  Dany Anglicheau  Jing Li  Jochen Reiser  Christophe Legendre  Patrick Bruneval  Tara Sigdel  George W Burke  Alessia Fornoni  Nada Alachkar  Guillaume Canaud  Annette Jackson 

PROVIDER: E-GEOD-57099 | ArrayExpress | 2014-11-04

SECONDARY ACCESSION(S): GSE57099PRJNA245423

REPOSITORIES: GEO, ArrayExpress

Dataset's files

Source:
Action DRS
E-GEOD-57099.idf.txt Idf
E-GEOD-57099.processed.1.zip Processed
E-GEOD-57099.raw.1.zip Raw
E-GEOD-57099.sdrf.txt Txt
Items per page:
1 - 4 of 4
altmetric image

Publications


Recurrence of focal segmental glomerulosclerosis (rFSGS) after kidney transplantation is a cause of accelerated graft loss. To evaluate pathogenic antibodies (Abs) in rFSGS, we processed 141 serum samples from 64 patients with and without primary rFSGS and 34 non-FSGS control patients transplanted at four hospitals. We screened about 9000 antigens in pretransplant sera and selected 10 Abs targeting glomerular antigens for enzyme-linked immunosorbent assay (ELISA) validation. A panel of seven Abs  ...[more]

Similar Datasets

2014-01-01 | S-EPMC4394366 | BioStudies
2011-01-01 | S-EPMC3719858 | BioStudies
2017-01-01 | S-EPMC5695800 | BioStudies
2018-01-01 | S-EPMC5828873 | BioStudies
2019-01-01 | S-EPMC6522053 | BioStudies
2019-01-01 | S-EPMC6776339 | BioStudies
2019-01-01 | S-EPMC6663006 | BioStudies
2011-01-01 | S-EPMC3103737 | BioStudies
2018-01-01 | S-EPMC6589822 | BioStudies
2018-01-01 | S-EPMC6278033 | BioStudies